lapatinib — CareFirst (Caremark)
Central nervous system metastases (CNS) from breast cancer
Initial criteria
- Treatment of brain metastases from HER2-positive breast cancer in combination with capecitabine
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months